Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy.
CRT
FDG
FMISO
HNSCC
Hypoxia
Radiomics
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
02
08
2019
accepted:
07
11
2019
pubmed:
28
11
2019
medline:
15
5
2021
entrez:
28
11
2019
Statut:
ppublish
Résumé
The aim of this study was to investigate whether textural features of tumour hypoxia, assessed with serial [ In a preliminary evaluation of a prospective trial, tumour hypoxia was evaluated in 29 patients via serial FMISO-PET before and during CRT. All patients received an initial [ Within a median follow-up of 29.6 months (95% CI: 16.8-48.0 months), no first-order metrics predicted OS with a significant GS (all p > 0.05) on any FMISO-PET scan. Only u Textural features on FMISO-PET scans before CRT, in week 2 and, to a limited degree, the change of features during CRT, were able to identify head and neck squamous cell carcinoma patients with better OS, suggesting that a higher homogeneity of the degree of hypoxia in tumours could correlate with a better outcome after CRT.
Identifiants
pubmed: 31773233
doi: 10.1007/s00259-019-04609-9
pii: 10.1007/s00259-019-04609-9
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1056-1064Références
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):133-40
pubmed: 23064544
Acta Oncol. 2016 Nov;55(11):1299-1304
pubmed: 27593107
Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):1989-99
pubmed: 18661128
J Nucl Med. 2011 Mar;52(3):369-78
pubmed: 21321270
Acta Oncol. 2015;54(9):1355-63
pubmed: 26398663
Radiother Oncol. 2017 Sep;124(3):533-540
pubmed: 28843726
Radiother Oncol. 2012 Oct;105(1):21-8
pubmed: 23022173
J Nucl Med. 2014 Mar;55(3):414-22
pubmed: 24549286
J Nucl Med. 2015 Jan;56(1):38-44
pubmed: 25500829
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4
pubmed: 17848275
J Nucl Med. 2013 Oct;54(10):1703-9
pubmed: 24042030
Acta Oncol. 2015;54(9):1364-9
pubmed: 26481464
J Clin Oncol. 2006 May 1;24(13):2098-104
pubmed: 16648512
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):965-8
pubmed: 21683887
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Clin Cancer Res. 2004 Apr 1;10(7):2245-52
pubmed: 15073099
Radiother Oncol. 2013 Sep;108(3):511-6
pubmed: 23849686
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
J Nucl Med. 2013 Jan;54(1):19-26
pubmed: 23204495
Transl Oncol. 2016 Apr;9(2):155-162
pubmed: 27084432
Radiother Oncol. 2006 Aug;80(2):151-6
pubmed: 16920211
Ann Nucl Med. 2017 Nov;31(9):678-685
pubmed: 28815452
Phys Med Biol. 2016 Jul 7;61(13):R150-66
pubmed: 27269645
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):419-28
pubmed: 25339524
Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
pubmed: 23149893
Radiother Oncol. 2015 Oct;117(1):113-7
pubmed: 26432067
Eur J Nucl Med Mol Imaging. 2018 May;45(5):768-786
pubmed: 29222685
Oncotarget. 2017 Jun 27;8(26):43169-43179
pubmed: 28574816
Strahlenther Onkol. 2012 Jul;188(7):616-27
pubmed: 22454045
Radiother Oncol. 2007 Jun;83(3):406-10
pubmed: 17543402
Radiother Oncol. 2005 Oct;77(1):18-24
pubmed: 16098619
Lancet. 2000 Mar 18;355(9208):949-55
pubmed: 10768432